E2730
Modify Date: 2025-08-25 11:03:43
E2730 structure
|
Common Name | E2730 | ||
|---|---|---|---|---|
| CAS Number | 1520073-91-9 | Molecular Weight | 284.23 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C9H8F4N2O2S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of E2730E2730 is a noncompetitive but selective inhibitor of gamma-aminobutyric acid (GABA) transporter 1 (GAT1) with orally available and antiepileptic activity. E2730-mediated GAT1 inhibition is positively correlated with environmental GABA levels and selectively inhibits GAT1-mediated GABA uptake. E2730 (5-50 mg/kg; po) in rat amygdala ignition model, and in mouse cornea ignition (5-50 mg/kg), drug resistance 6Hz-44mA has demonstrated in vivo efficacy in models of psychomotor epilepsy (5-50 mg/kg), fragile X syndrome (2.5-300 mg/kg), and Dravet syndrome (10 mg/kg, 20 mg/kg)[1]. |
| Name | E2730 |
|---|
| Description | E2730 is a noncompetitive but selective inhibitor of gamma-aminobutyric acid (GABA) transporter 1 (GAT1) with orally available and antiepileptic activity. E2730-mediated GAT1 inhibition is positively correlated with environmental GABA levels and selectively inhibits GAT1-mediated GABA uptake. E2730 (5-50 mg/kg; po) in rat amygdala ignition model, and in mouse cornea ignition (5-50 mg/kg), drug resistance 6Hz-44mA has demonstrated in vivo efficacy in models of psychomotor epilepsy (5-50 mg/kg), fragile X syndrome (2.5-300 mg/kg), and Dravet syndrome (10 mg/kg, 20 mg/kg)[1]. |
|---|---|
| Related Catalog | |
| Target |
γ-aminobutyric acid (GABA) transporter 1 (GAT1)[1] |
| References |
| Molecular Formula | C9H8F4N2O2S |
|---|---|
| Molecular Weight | 284.23 |
| InChIKey | ZDUAYVUFBARRPR-QMMMGPOBSA-N |
| SMILES | NS(=O)(=O)NC1c2c(F)cc(F)cc2CC1(F)F |